Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CAFCIT vs CAFFEINE CITRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Caffeine citrate is a central nervous system stimulant. It competitively blocks adenosine receptors (A1 and A2A subtypes), leading to increased neuronal firing and release of neurotransmitters such as dopamine and norepinephrine. In neonates, it stimulates respiratory centers, increases minute ventilation, and improves sensitivity to hypercapnia.
Caffeine is a methylxanthine that acts as a central nervous system stimulant. It competitively antagonizes adenosine receptors (A1 and A2A subtypes), leading to increased neuronal firing and neurotransmitter release. It also inhibits phosphodiesterase, resulting in elevated intracellular c AMP levels, and enhances calcium release from sarcoplasmic reticulum in muscle cells, promoting contractility.
FDA: Treatment of apnea of prematurity in neonates.,Off-label: Prevention of apnea of prematurity, postoperative respiratory depression in neonates, and as a respiratory stimulant in various settings.
Treatment of apnea of prematurity in neonates,Improvement of respiratory function in premature infants,Off-label: adjunctive treatment for migraine headaches,Off-label: enhancement of alertness and psychomotor performance
Caffeine citrate: IV or PO, loading dose 20 mg/kg (caffeine base) once, then maintenance 5 mg/kg (caffeine base) once daily. Onset of action: 15-30 minutes IV; peak effect: 30-120 minutes. Duration: 40-100 hours.
20 mg/kg caffeine citrate (equivalent to 10 mg/kg caffeine base) IV over 30 minutes as a single loading dose, followed by a maintenance dose of 5-10 mg/kg caffeine citrate (2.5-5 mg/kg caffeine base) IV once daily, starting 24 hours after the loading dose.
Terminal elimination half-life: In neonates (postmenstrual age 28-44 weeks), 40-230 hours (mean ~100 hours); in adults, 3-6 hours. Clinical context: Prolonged in preterm neonates due to immature hepatic function.
Adults: 3-6 hours (mean 5 hours). Neonates: 40-230 hours (mean 80 hours) due to immature hepatic clearance; clinical context: prolonged half-life in preterm infants requires dosing interval adjustment (usually 24 hours).
Primarily hepatic via cytochrome P450 1A2 (CYP1A2) to paraxanthine, theobromine, and theophylline. Minor metabolism via CYP3A4, CYP2E1, and N-acetyltransferase.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2) to paraxanthine, theobromine, and theophylline. Also undergoes N-demethylation and oxidation.
Renal: approximately 86% as unchanged drug and metabolites (paraxanthine, theophylline, theobromine) with about 1% unchanged; biliary/fecal: negligible.
Renal excretion (86% as unchanged drug and metabolites; 1% as caffeine, 85% as paraxanthine and other metabolites). Fecal excretion is minimal (<2%).
Approximately 36% bound to serum albumin in neonates; in adults, about 50% bound to albumin.
25-36% bound primarily to albumin. Less bound compared to other methylxanthines (e.g., theophylline).
Neonates: 0.8-1.0 L/kg; adults: 0.4-0.6 L/kg. Clinical meaning: Reflects distribution into body water, with higher Vd in neonates due to higher total body water.
0.4-0.6 L/kg in adults. In neonates: 0.8-1.0 L/kg (higher Vd due to greater total body water). Clinical meaning: reflects distribution into total body water and tissues.
Oral: 85-100% (well absorbed); intravenous: 100%.
Oral: 100% (rapidly and completely absorbed). Intravenous: 100% (given as citrate salt; bioavailability of caffeine base is equivalent).
No specific GFR-based dose adjustments are recommended; however, monitor for accumulation in renal impairment due to prolonged half-life (up to 100 hours in neonates). Consider reducing dose or extending interval if severe renal dysfunction.
No dose adjustment required for mild to moderate renal impairment. In severe renal impairment (GFR <30 m L/min/1.73 m²), use caution and consider reducing maintenance dose by 50% due to potential accumulation.
No specific Child-Pugh based adjustments provided. Caution in severe hepatic impairment due to prolonged clearance. Monitor for adverse effects.
In mild hepatic impairment (Child-Pugh class A), no adjustment. In moderate to severe hepatic impairment (Child-Pugh class B or C), reduce loading dose by 50% and maintenance dose by 50-75% due to decreased clearance.
Neonates (≤28 days): Caffeine citrate IV or PO; loading dose 20 mg/kg (caffeine base) once, then maintenance 5 mg/kg (caffeine base) once daily starting 24 hours after loading. Adjust to maintain therapeutic plasma levels (5-25 mg/L). Infants >28 days and children: dosing not established for apnea of prematurity; use weight-based dosing with caution.
Neonates: Loading dose of 20 mg/kg caffeine citrate (10 mg/kg caffeine base) IV over 30 minutes, followed by maintenance of 5-10 mg/kg caffeine citrate (2.5-5 mg/kg caffeine base) IV or orally once daily. For infants >28 days and children: not routinely recommended; use with caution and adjust based on clinical response.
No specific dose adjustments in elderly; consider lower initial doses due to possible reduced clearance and increased sensitivity to CNS stimulation.
No specific dose adjustment based on age alone. However, elderly patients may have reduced renal function and increased sensitivity to adverse effects (e.g., tachycardia, agitation). Monitor closely and consider starting at lower end of dosing range (e.g., 5 mg/kg caffeine citrate maintenance).
None.
None.
Use with caution in neonates with seizure disorders, as caffeine may lower seizure threshold.,Monitor for signs of toxicity including tachycardia, irritability, and feeding intolerance.,Renal impairment may prolong half-life; adjust dose in severe renal dysfunction.,Hepatic impairment may reduce clearance.,May exacerbate gastroesophageal reflux disease (GERD).
Use with caution in patients with history of peptic ulcer disease, gastroesophageal reflux, or hiatal hernia,May exacerbate anxiety, insomnia, or cardiac arrhythmias,Monitor for caffeine toxicity in neonates: tachycardia, tachypnea, jitteriness, feeding intolerance,Slow clearance in premature infants; adjust dose based on plasma levels,Avoid sudden discontinuation to prevent withdrawal symptoms
Hypersensitivity to caffeine or any component of the formulation.,History of serious cardiac arrhythmias (e.g., ventricular tachycardia).
Hypersensitivity to caffeine or any component of the formulation,Concurrent use with theophylline or other xanthine derivatives (additive toxicity),History of severe cardiac arrhythmias
No significant food interactions. Avoid caffeine-containing products (coffee, tea, soda, chocolate) due to additive stimulant effects.
No significant food interactions for caffeine citrate when administered intravenously. For oral administration, avoid excessive caffeine-containing foods or beverages (e.g., coffee, tea, soda) in breastfeeding mothers as it may pass into breast milk and affect the infant.
Caffeine (Cafcit) is FDA Pregnancy Category C. In first trimester, studies suggest possible association with low birth weight but not major malformations. Avoid high doses. In second and third trimesters, caffeine crosses placenta; high maternal intake linked with reduced uteroplacental blood flow, fetal growth restriction, and preterm birth. Avoid excessive intake.
In the first trimester, high caffeine intake (>200-300 mg/day) is associated with a modestly increased risk of miscarriage. In the second and third trimesters, excessive caffeine may contribute to fetal growth restriction and low birth weight. No consistent evidence of major malformations. Caffeine citrate is generally avoided or used with caution during pregnancy.
Caffeine enters breast milk: M/P ratio ~0.5-0.76. Infant levels generally low unless maternal intake >300 mg/day; possible irritability, poor sleep in infants. Use lowest effective dose. Monitor infant for excitation. Not contraindicated.
Caffeine is excreted into breast milk; M/P ratio approximately 0.5-0.8. Infant exposure is typically low with moderate maternal intake, but accumulation can occur in neonates. The American Academy of Pediatrics considers caffeine compatible with breastfeeding with caution.
Pregnancy prolongs caffeine half-life due to decreased CYP1A2 activity, especially in second and third trimesters (half-life may increase from 3-6h to 10-20h). Consider reducing dose or frequency; avoid high boluses. Individualize based on clinical response and maternal side effects.
Pregnancy decreases caffeine clearance by up to 50% in the second and third trimesters. To avoid toxicity, reduce maternal caffeine intake (e.g., limit to <200 mg/day). If caffeine citrate is used therapeutically (e.g., for neonatal apnea), dosing in pregnant women should be based on individual clearance; lower doses may be required.
CAFCIT (caffeine citrate) is used for apnea of prematurity. Loading dose: 20 mg/kg IV/PO; maintenance: 5-10 mg/kg/day. Therapeutic levels 8-20 mg/L; monitor for tachycardia, feeding intolerance. Reduce dose with hepatic impairment. Discontinue if seizures occur.
Caffeine citrate is used for apnea of prematurity. Therapeutic levels: 5-25 mcg/m L. Dosing: loading dose 20 mg/kg IV, then maintenance 5 mg/kg/day. Monitor for tachycardia, jitteriness, feeding intolerance. Caffeine clearance is slower in neonates; dose adjustments may be needed with hepatic impairment or concomitant medications like cimetidine. Caffeine base vs. citrate: 1 mg caffeine base = 2 mg caffeine citrate.
This medication helps your baby breathe more regularly by stimulating the respiratory center.,It may cause increased heart rate, jitteriness, or feeding problems.,Do not give extra caffeine (coffee, tea, cola) while on this medicine.,Report any signs of irritability, vomiting, or seizures to the doctor immediately.
This medication stimulates breathing in premature infants and is given intravenously or orally.,Do not stop the medication abruptly without consulting the doctor.,Monitor your baby for any signs of fast heart rate, irritability, or poor feeding and report to healthcare provider.,Keep all follow-up appointments for blood level monitoring and assessment.,Inform the doctor about any other medications your baby is taking, as interactions may occur.
No interactions on record
"Triamterene, a potassium-sparing diuretic, can inhibit the hepatic metabolism of caffeine by competing for cytochrome P450 (CYP) 1A2, the primary enzyme responsible for caffeine clearance. This leads to increased plasma caffeine concentrations and prolonged caffeine half-life, potentially causing caffeine toxicity manifesting as nervousness, insomnia, tachycardia, and diuresis enhancement. Patients may experience exaggerated stimulant effects and increased risk of cardiac arrhythmias when combining these agents."
"Caffeine inhibits the metabolism of sulfadiazine by competitively antagonizing cytochrome P450 (CYP) enzymes, particularly CYP1A2, leading to increased plasma concentrations of sulfadiazine. This elevates the risk of dose-dependent adverse effects, including crystalluria, nephrotoxicity, and hypersensitivity reactions. The interaction may also reduce the therapeutic efficacy of sulfadiazine due to altered pharmacokinetics."
"Caffeine inhibits the cytochrome P450 enzyme CYP2C9, which is primarily responsible for the metabolism of losartan to its active metabolite E-3174. This inhibition can lead to increased plasma concentrations of losartan and decreased formation of the active metabolite, potentially reducing losartan's antihypertensive efficacy. The clinical outcome may be suboptimal blood pressure control in patients consuming high amounts of caffeine."
Common clinical questions about CAFCIT vs CAFFEINE CITRATE, answered by our medical review team.
CAFCIT is a Respiratory Stimulant (Xanthine) that works by Caffeine citrate is a central nervous system stimulant. It competitively blocks adenosine receptors (A1 and A2A subtypes), leading to increased neuronal firing and release of neurotransmitters such as dopamine and norepinephrine. In neonates, it stimulates respiratory centers, increases minute ventilation, and improves sensitivity to hypercapnia.. CAFFEINE CITRATE is a Respiratory Stimulant (Xanthine) that works by Caffeine is a methylxanthine that acts as a central nervous system stimulant. It competitively antagonizes adenosine receptors (A1 and A2A subtypes), leading to increased neuronal firing and neurotransmitter release. It also inhibits phosphodiesterase, resulting in elevated intracellular c AMP levels, and enhances calcium release from sarcoplasmic reticulum in muscle cells, promoting contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CAFCIT and CAFFEINE CITRATE depend on the specific clinical indication. These are both Respiratory Stimulant (Xanthine) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CAFCIT is: Caffeine citrate: IV or PO, loading dose 20 mg/kg (caffeine base) once, then maintenance 5 mg/kg (caffeine base) once daily. Onset of action: 15-30 minutes IV; peak effect: 30-120 minutes. Duration: 40-100 hours.. The standard adult dose of CAFFEINE CITRATE is: 20 mg/kg caffeine citrate (equivalent to 10 mg/kg caffeine base) IV over 30 minutes as a single loading dose, followed by a maintenance dose of 5-10 mg/kg caffeine citrate (2.5-5 mg/kg caffeine base) IV once daily, starting 24 hours after the loading dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CAFCIT and CAFFEINE CITRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CAFCIT is classified as Category C. Caffeine (Cafcit) is FDA Pregnancy Category C. In first trimester, studies suggest possible association with low birth weight but not major malformations. Avoid high doses. In seco. CAFFEINE CITRATE is classified as Category C. In the first trimester, high caffeine intake (>200-300 mg/day) is associated with a modestly increased risk of miscarriage. In the second and third trimesters, excessive caffeine m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.